Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer (DISCO)

Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer Patients; a Multicenter Randomized Trial

MRI is a potentially powerful tool to reliably determine the intra-abdominal tumor load and relations with intra-abdominal organs. In recent years diffusion weighted MRI has proven its value as a highly sensitive technique to detect small malignant disease in a wide variety of cancers [1-3]. However, literature concerning the clinical impact of detecting peritoneal metastases with MRI is very limited. Therefore, there is a need for a large randomized multicenter trial to determine whether dedicated MRI can be used as a selection tool for CRS-HIPEC candidates in daily practice.

Study Overview

• Status: Recruiting
• Conditions: MRI; Colorectal Cancer; Peritoneal Carcinomatosis
• Intervention / Treatment: Diagnostic test: DWI MRI of the pelvis, abdomen and thorax

Detailed Description

HYPOTHESIS Staging with dedicated MRI will lead to a reduction of staging laparoscopies and explorative laparotomies in colorectal patients with PM to evaluate whether they may benefit from CRS-HIPEC

OBJECTIVES The goal is to perform a multicenter randomized study to compare a less invasive diagnostic workup ARM A (with MRI and surgical inspection reserved for borderline operable cases on MRI) to the standard diagnostic workup (ARM B, without MRI, with surgical staging to determine resectability based on a MDT decision) of patients with (suspected) peritoneal metastases. Surgical staging laparoscopies may largely be replaced by MRI (only reserved as a problem solver for borderline operable cases in ARM A). If it will be proven that MRI is an accurate, robust and cost-effective staging tool than this will result in a more patient friendly diagnostic workup with less futile surgical procedures.

STUDY DESIGN 4-year multicenter randomized controlled trial

STUDY POPULATION N=272 patients suspected of synchronous or metachronous peritoneal metastases of colorectal origin who are considered for CRS-HIPEC after CT imaging.

EXPERIMENTAL (ARM A) CRS-HIPEC candidates are selected based on MRI and only in borderline cases a surgical inspection will be performed

CONTROL (ARM B) Standard work-up including computed tomography and surgical inspection as appropriate (based on a MDT decision).

MAIN STUDY PARAMETERS/ENDPOINTS

Primary outcome:

Number of preventable unnecessary laparoscopies and explorative laparotomies.

NATURE AND EXTENT OF THE BURDEN AND RISKS ASSOCIATED WITH PARTICIPATION, BENEFIT AND GROUP RELATEDNESS:

MRI is a standard diagnostic procedure without the use of radiation. The MR sequences, MR-contrast agents and Buscopan (to minimize peristaltic bowel movements) are all commonly used in daily clinical practice. In addition, patients will be asked to drink 1L of pineapple juice 1-2 hours before the MRI (to minimize signal in the bowel lumen and optimize image quality), which is standard procedure in many clinics for MRCP and MR enterography. By acting upon the MRI findings in the experimental arm A, could result into new risks as oppose to standard clinical practice. However by introducing the borderline group ('yellow light' group) to receive diagnostic laparoscopy will minimize the possibility of over-staging a patient that would have received a successful CRS/HIPEC in de control arm. In our internal pilot data of 87 patients considered for CRS/HIPEC, no patients with a PCI of above 24 ended up receiving successful CRS/HIPEC and only 4 of the 15 patients that could have been assigned to the borderline group (were the trail to have run at that time) received successful CRS/HIPEC.

• Study Type: Interventional
• Enrollment (Anticipated): 272
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Max Lahaye, PhD MD; Phone Number: +31 20 512 1012; Email: m.lahaye@nki.nl
• Study Contact Backup: Name: Carine Sondermeijer, Bsc; Phone Number: +31 20 512 7423; Email: c.sondermeijer@nki.nl

Study Locations

• Netherlands
  • Amsterdam, Netherlands, 1066CX
    • Recruiting
    • Antoni van Leeuwenhoek
    • Contact: Carine Sondermeijer, Bsc; Phone Number: +31 20 512 7423; Email: c.sondermeijer@nki.nl
    • Contact: Max Lahaye, PhD, MD; Phone Number: +31 20 512 1012; Email: m.lahaye@nki.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with suspicion of colorectal peritoneal metastases and considered for CRS/HIPEC

  • Age ≥18 years
  • Written and signed informed consent
  • WHO 0-2
  • Able and willing to drink 1 liter of pineapple or blueberry juice

Exclusion Criteria:

• - Patients with contraindications for the MRI:
• Patients who have a heart pacemaker may not have an MRI scan
• Patients who have a metallic foreign body (metal sliver) in their body
• Patients with severe claustrophobia
• Ineligible to receive gadofosveset (Gadolinium) contrast (history of contrast allergy, impaired kidney function with a Glomerular Filtration Rate <30 ml/min/1.73m2)
• Ineligible to receive Buscopan
• Allergy for pineapple juice and blueberry juice.
• Patients with clinical contraindications for CRS/HIPEC
• Patients with radiological contra-indications for CRS/HIPEC observed on CT thorax/abdomen
• Massive mesenteric or small bowel involvement which would lead to short bowel syndrome if adequately resected
• Extra-peritoneal metastases for which CRS/HIPEC is not justifiable (such as lung metastases, skeletal metastases, and liver metastases)
• Inoperable retroperitoneal lymphadenopathy
• Patients with a known additional malignancy, unless o treated with curative intent at least five years ago. in situ cancers, basal cell carcinoma of the skin or squamous cell carcinoma of the skin that have undergone potentially curative therapy within the past five years

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: experimental arm A; patients will undergo dedicated MRI imaging of the pelvis, abdomen, and thorax. Based on the findings of the MRI scan patients will be allocated to one of the diagnostic/treatment options	Diagnostic test: DWI MRI of the pelvis, abdomen and thorax; Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
No Intervention: arm B; patients will undergo the current standard diagnostic work-up of DLS at indication (MDT decision) and otherwise continue to CRS-HIPEC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of preventable unnecessary laparoscopies and explorative laparotomies defined as:	(I) patients with a PCI<15 at laparoscopy or PCI>24 at laparotomy (II) incomplete CRS-HIPEC (R2A/R2B/open-close procedures)	4 weeks
Number of preventable unnecessary laparoscopies and explorative laparotomies defined as	(II) incomplete CRS-HIPEC (R2A/R2B/open-close procedures)	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
- Number of additional extra-peritoneal findings	Number of additional extra-peritoneal findings	4 weeks
- Number of early recurrences (with-in 6 months after R1 resection and HIPEC)	- Number of early recurrences (with-in 6 months after R1 resection and HIPEC)	6 months
- Diagnostic performance of Peritoneal Cancer Index determined by MRI (MRI-PCI) to predict surgical Peritoneal Cancer Index (S-PCI).	- The Peritoneal Cancer Index (PCI) system reported by Sugerbaker [24] will be determined by indicating the presence of large (>5cm), moderate (<5cm - >0.5cm), small (<0.5cm) or no involvement in 13 abdominal regions	6 months
- Inter-observer agreement between different readers for DW-MRI.	Readers will evaluate the following MR criteria that might result in an incomplete CRS with a confidence level score (0 to 5): MRI-PCI > 20; Extensive agglutinated intra-abdominal disease (stomach/liver/spleen/retrohepatic); Extensive serosa involvement (>1.5 m bowel resection needed); Extensive disease at diaphragmatic level (>1 cm in diameter); Extensive extra-abdominal disease (>1 cm in diameter) in patients without neoadjuvant treatment; Presence and location of intra-abdominal enlarged lymph nodes; Ascites > 500 ml; Overall resectability based on MRI findings	6 months
Incremental cost-effectiveness ratio	The direct costs will include costs of standard treatment (chemotherapy and cytoreductive surgery), costs of diagnostic work-up (standard and MRI) and treatment of adverse events/surgical complications, follow-up visits, recurrences and palliative care (measured as possible within the trial period). From this the cost effectiveness will be determined.	6 months
Quality of Life between diagnostic arms by EORTC-C30 -	The following questionnaire will be used to measure HRQoL in patients EORTC-C30. This will be completed at baseline, 3 & 6 months following randomisation.	6 months
Quality of Life between diagnostic arms by EQ5D5L	The following questionnaire will be used to measure HRQoL in patients EQ5D5L. This will be completed at baseline, 3 & 6 months following	6 months

Collaborators and Investigators

• Sponsor: The Netherlands Cancer Institute
• Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
• Investigators: Principal Investigator: Max Lahaye, PhD MD, Antoni van Leeuwenhoek

Publications and helpful links

General Publications

• Engbersen MP, Rijsemus CJV, Nederend J, Aalbers AGJ, de Hingh IHJT, Retel V, Lambregts DMJ, Van der Hoeven EJRJ, Boerma D, Wiezer MJ, De Vries M, Madsen EVE, Brandt-Kerkhof ARM, Van Koeverden S, De Reuver PR, Beets-Tan RGH, Kok NFM, Lahaye MJ. Dedicated MRI staging versus surgical staging of peritoneal metastases in colorectal cancer patients considered for CRS-HIPEC; the DISCO randomized multicenter trial. BMC Cancer. 2021 Apr 26;21(1):464. doi: 10.1186/s12885-021-08168-x.

Study record dates

Study Major Dates

• Study Start (Actual): October 28, 2019
• Primary Completion (Anticipated): October 28, 2023
• Study Completion (Anticipated): October 28, 2023

Study Registration Dates

• First Submitted: October 31, 2019
• First Submitted That Met QC Criteria: January 13, 2020
• First Posted (Actual): January 18, 2020

Study Record Updates

• Last Update Posted (Actual): January 18, 2020
• Last Update Submitted That Met QC Criteria: January 13, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Keywords: MRI; Colorectal cancer; Randomization; Peritoneal Carcinomatosis
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Peritoneal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Abdominal Neoplasms; Carcinoma; Colorectal Neoplasms; Peritoneal Neoplasms
• Other Study ID Numbers: M19DSC

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No